CClinicalTrials.gg
Approved for marketingNCT02762591Updated Apr 18, 2017

Expanded Access of Pimavanserin for Patients With PD Psychosis

An expanded access record providing Pimavanserin tartrate in Parkinson's Disease Psychosis, sponsored by ACADIA Pharmaceuticals Inc.. Approved for marketing. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-04-18.

Sponsored by ACADIA Pharmaceuticals Inc. · Expanded access

Study type
Expanded access
Ages
40 Years and older
Sex
All
01

Study summary

The purpose of this program is to provide patients with PDP access to pimavanserin until the product receives marketing approval from the FDA and is commercially available.

02

Conditions studied

03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

Browse Parkinson Disease studies →

Lead sponsor

ACADIA Pharmaceuticals Inc. is the lead sponsor of 41 studies on the registry; 5 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 23 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All

Inclusion criteria

  1. Patient meets one of the following criteria:

    1. Patient has participated in a previous study of pimavanserin for Parkinson's disease psychosis (PDP)
    2. New ("De novo") patients
  2. A clinical diagnosis of Parkinson's disease with a minimum duration of 1 year
  3. Female patients must be of non-childbearing potential
  4. Psychotic symptoms must have developed after Parkinson's disease diagnosis was established
  5. Patient that has received stereotaxic surgery for subthalamic nucleus deep brain stimulation must be at least 6 months post-surgery and the stimulator settings must have been stable for at least 1 month prior to Study Day 1 (Baseline) and must remain stable during the trial
  6. The patient or Legally Authorized Representative (LAR) is willing and able to provide consent
  7. The patient or LAR is willing and able to adequately communicate in English.

Exclusion criteria

Exclusion Criteria:

  1. Patient has a history of significant psychotic disorders prior to or concomitantly with the diagnosis of Parkinson's disease including, but not limited to, schizophrenia or bipolar disorder
  2. Patient has had dementia prior to or concurrently with their diagnosis of Parkinson's disease that may be inconsistent with a Parkinson's diagnosis
  3. Patient has current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic, or other medical disorder, including cancer or malignancies, which would affect the patient's ability to participate in the program
  4. Patient has had a myocardial infarction in last six months
  5. Patient has any surgery planned during the screening, treatment, or follow-up periods

Patients will be evaluated at screening to ensure that all criteria for study participation are met. These evaluations will include specific measures of psychosis severity, delirium, dementia, cardiovascular condition, and pregnancy status. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline health and psychiatric condition do not meet all pre-specified entry criteria).

05

Access details

Study type
Expanded access

Available treatment

  • DrugPimavanserin tartrate

    Pimavanserin tartrate 40 mg, tablet, taken as two 20 mg tablets, once daily by mouth

06

Where to request access

No study locations are listed for this record.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT02762591
Lead sponsor
ACADIA Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
May 5, 2016
Last update
Apr 18, 2017
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion